Literature DB >> 1749643

The prognosis with postherpetic neuralgia.

Peter N C Watson1, Verna R Watt, Mary Chipman, Nicholas Birkett, Ramon J Evans.   

Abstract

One hundred and fifty-six patients with moderate to severe postherpetic neuralgia (PHN) were followed for up to 11 years. Nearly half of all patients were doing well at the final assessment (median 2 years) and more than half of these were on no therapy at this time. The most commonly used agents associated with a good outcome were antidepressants, topical capsaicin and analgesics of various kinds. Longer duration PHN appeared to have a worse prognosis. More of these patients were noted to be using some form of treatment at follow up. A group of patients seemed to follow a progressive course and were refractory to all treatments used in this study.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1749643     DOI: 10.1016/0304-3959(91)90076-A

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  23 in total

1.  Chronic pain associated with the Chikungunya Fever: long lasting burden of an acute illness.

Authors:  Daniel Ciampi de Andrade; Sylvain Jean; Pierre Clavelou; Radhouane Dallel; Didier Bouhassira
Journal:  BMC Infect Dis       Date:  2010-02-19       Impact factor: 3.090

Review 2.  Postherpetic neuralgia.

Authors:  Peter N Watson
Journal:  BMJ Clin Evid       Date:  2010-10-08

Review 3.  The management of postherpetic neuralgia.

Authors:  D Bowsher
Journal:  Postgrad Med J       Date:  1997-10       Impact factor: 2.401

4.  The cost of treatment for post-herpetic neuralgia in the UK.

Authors:  L Davies; L Cossins; D Bowsher; M Drummond
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

5.  Characterization of the host immune response in human Ganglia after herpes zoster.

Authors:  Kavitha Gowrishankar; Megan Steain; Anthony L Cunningham; Michael Rodriguez; Peter Blumbergs; Barry Slobedman; Allison Abendroth
Journal:  J Virol       Date:  2010-06-23       Impact factor: 5.103

Review 6.  Post-herpetic neuralgia in older patients. Incidence and optimal treatment.

Authors:  D Bowsher
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

7.  Natural history of pain following herpes zoster.

Authors:  Hans Gustav Thyregod; Michael C Rowbotham; Michelle Peters; Jessica Possehn; Marlene Berro; Karin Lottrup Petersen
Journal:  Pain       Date:  2006-10-27       Impact factor: 6.961

Review 8.  Varicella zoster virus infection.

Authors:  Anne A Gershon; Judith Breuer; Jeffrey I Cohen; Randall J Cohrs; Michael D Gershon; Don Gilden; Charles Grose; Sophie Hambleton; Peter G E Kennedy; Michael N Oxman; Jane F Seward; Koichi Yamanishi
Journal:  Nat Rev Dis Primers       Date:  2015-07-02       Impact factor: 52.329

9.  Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older.

Authors:  Santosh C Sutradhar; William W B Wang; Katia Schlienger; Jon E Stek; Jin Xu; Ivan S F Chan; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2009-03-04

10.  Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.

Authors:  Ronald R White; Greg Lenhart; Puneet K Singhal; Ralph P Insinga; Robbin F Itzler; James M Pellissier; Arthur W Segraves
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.